Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

To define effects of treatment with teriparatide followed by denosumab on lumbar spine (LS) volumetric bone mineral density (vBMD) and stiffness by finite element analysis assessed on central quantitative computed tomography (cQCT) scans.

Why It Was Studied

Premenopausal women with idiopathic osteoporosis (PreMenIOP) have marked deficits in bone density, microstructure, and strength.

Who Took Part

According to the abstract, 41 women were involved.

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Teriparatide group a baseline to be compared against.

The methods mention a period of 6 months.

After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months.

What Was Measured

Topics PubMed links to this paper include Bone Density, Bone Density Conservation Agents, Denosumab, Lumbar Vertebrae, Osteoporosis, Osteoporosis, Postmenopausal and Teriparatide.

Author keywords: central QCT, premenopausal osteoporosis, stiffness and volumetric BMD.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teriparatide in 41 women over 6 months.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Teriparatide compound page, all human trials.